FDA 483 - DLC Laboratories, Inc - January 31, 2025

An FDA inspection of DLC Laboratories, Inc. in Paramount, CA, a drug manufacturer, revealed a significant deficiency in their quality system. The firm failed to establish written procedures for production and process controls, specifically regarding the evaluation of nitrosamine impurities in amine-containing products. This indicates a moderate severity issue related to drug product quality assurance and control.